Document is current
Any future updates will be listed below
-
Authors
Coyne, Karin S.
Harrington, Amanda
Currie, Brooke M.
Chen, Jun
Gillard, Patrick
Spies, James B.
-
Funding
Funding for this research was provided by:
Allergan (n/a)
-
License Information
Text and Data Mining valid from 2019-08-23
Version of Record valid from 2019-08-23
-
More Information
Article History
Received: 11 January 2019
Accepted: 6 August 2019
First Online: 23 August 2019
Ethics approval and consent to participate
: Each institution involved in the original studies, VENUS I and VENUS II, obtained approval from a central or local Institutional Review Board (IRB) before study initiation, and written informed consent was acquired from all study participants. The institutions involved were approved by one of the following IRBs: Shulman Associates IRB, Western IRB, Medical University of South Carolina IRB, Hamilton Integrated Research Ethics Board, Ottawa Health Science Network Research Ethics Board, Chesapeake IRB, and Virtua General IRB.
: Not applicable.
: Karin S. Coyne, Brooke M. Currie, and Jun Chen are employees of Evidera, and received funding from Allergan to conduct this study. Amanda Harrington and Patrick Gillard are employees of Allergan. James B. Spies has nothing to disclose.
